+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial



Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial



American Journal of Health-System Pharmacy 72(7): 557-562



An audit was conducted to determine if the benefits of dabigatran treatment, as demonstrated in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, are applicable to patients with nonvalvular atrial fibrillation managed by a pharmacist-run anticoagulation clinic (PAC). The records of warfarin-treated patients managed by a PAC program over a three-year period were screened to identify patients with diagnosed nonvalvular atrial fibrillation and a goal International Normalized Ratio (INR) of 2-3; the case selection criteria were similar to those used in the RE-LY trial. Abstracted data included dates and results of INR monitoring and information needed to calculate CHADS2 (Congestive Heart Failure, Hypertension, Age, Diabetes, and Stroke [doubled]) scores. Warfarin time in the therapeutic range (TTR) was the primary endpoint. A pairwise comparison of TTR distributions in subsets of patients grouped by CHADS2 score was performed to test the hypothesis that any two groups had identical distributions. Data on 314 PAC patients, including 9772 INR values, were analyzed. The mean±S.D. TTR was 62.4%±24.5% (median, 66.7%), which was similar to the mean TTR reported in the RE-LY trial (p=0.092). The distribution of TTR values in the PAC population differed significantly in patients with a CHADS2 score of 2 versus a score of 3 (p=0.0333 for Kuiper test), but no other significant differences were noted. TTR values among PAC-managed patients with nonvalvular atrial fibrillation were comparable to those reported in the RE-LY trial.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057473746

Download citation: RISBibTeXText

PMID: 25788509

DOI: 10.2146/ajhp130800


Related references

Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic. Journal of the American Heart Association 2(4): E000170, 2013

Pharmacist's interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. International Journal of Clinical Pharmacy 40(5): 1078-1085, 2018

Quality of anticoagulation care in patients discharged from a pharmacist-managed anticoagulation clinic after stabilization of warfarin therapy. PharmacoTherapy 28(1): 20-26, 2008

Impact of a pharmacist-managed inpatient anticoagulation service for warfarin titration with follow-on care at outpatient anticoagulation clinic. Journal of Thrombosis and Thrombolysis 25(1): 133-133, 2008

Prevalent etiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics. Journal of Thrombosis and Thrombolysis 25(1): 120-120, 2008

Prevalent aetiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics. Journal of Clinical Pharmacy and Therapeutics 36(1): 64-70, 2011

Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients. Journal of Thrombosis and Thrombolysis 42(2): 283-287, 2016

Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. American Journal of Hospital Pharmacy 42(2): 304-308, 1985

Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice. Canadian Family Physician Medecin de Famille Canadien 63(10): E425-E431, 2017

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children. Journal of Thrombosis and Haemostasis 9(5): 1090-1092, 2011

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2331-2332, 2012

Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin. Postgraduate Medical Journal 94(1110): 207-211, 2018

Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin. Frontiers in Pharmacology 9: 1052, 2018

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2332-2333, 2012

Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions. American Journal of Health-System Pharmacy 53(13): 1580-1583, 1996